Open AccessTranslational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts
Author(s) -
Stephan Krüger,
Michael Haas,
Steffen Ormanns,
Sibylle Bächmann,
Jens T. Siveke,
Thomas Kirchner,
Volker Heinemann,
Stefan Boeck
Publication year - 2014
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v20.i31.10769
Subject(s) - medicine , erlotinib , folinic acid , oncology , oxaliplatin , irinotecan , translational research , pancreatic ductal adenocarcinoma , gemcitabine , cetuximab , pancreatic cancer , regimen , epidermal growth factor receptor , chemotherapy , cancer , colorectal cancer , pathology
Pancreatic ductal adenocarcinoma (PDA) is one of the major causes for cancer death worldwide. Treatment of metastatic disease remains challenging as only certain patients benefit from advances made with the intensified chemotherapy regimen folinic acid, irinotecan and oxaliplatin, the epidermal growth factor receptor inhibitor erlotinib or the recently FDA-approved nab-paclitaxel. Up to date, no established approach for prediction of treatment response or specific treatment allocation exists. Translational research was able to identify a number of potential biomarkers that might help to improve the dismal prognosis of PDA by facilitating upfront treatment allocation. This topic highlight is focused on current evidence on potential biomarkers for tumor biology, prognosis and prediction of treatment efficacy.